Evaluation of behavioural and neurochemical effects of psilocybin in mice subjected to chronic unpredictable mild stress. - Erkizia-Santamaría I; Horrillo I; Martínez-Álvarez N; Pérez-Martínez D; Rivero G; Erdozain AM; Meana JJ; Ortega JE. (2025)

The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder - COMPASS Pathways (ClinicalTrials.gov, 2025)

Synergistic behavioral and neuroplastic effects of psilocybin-NMDAR modulator administration. - Ben-Tal T; Pogodin I; Botvinnik A; Lifschytz T; Heresco-Levy U; Lerer B. (2025)

Mycelium Growth and Development of Psilocybe spp. Mother Cultures on Agar-Based Media. - Pepe M; Hesami M; Fleishmann L; Hsiang T; Jones AMP. (2025)

A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of MLS101 (Psilocybin) in Healthy Participants - MycoMedica Life Sciences PBC (ClinicalTrials.gov, 2025)

Psilocybin-Assisted Therapy Increases Self-Compassion in Patients with Alcohol Use Disorder - Agin-Liebes G; Petridis P; Zeifman R; Link M; Cordova MJ; Bogenschutz M. (PsyArXiv, 2025)

Comparison of the Effects of PEX20 (Oral Psilocin), PEX30 (Sublingual Psilocin), and PEX10 (Oral Psilocybin) in Healthy Adults - University of California; San Francisco (ClinicalTrials.gov, 2025)

Psilocybin-Assisted Therapy Increases Self-Compassion in Patients with Alcohol Use Disorder (PsyArXiv, 2025)

Psilocybin and hallucinogenic mushrooms - ERRATUM. - Fradet M; Kelly CM; Donnelly AJ; Suppes T. (2025)

Long-term outcomes of single-dose psilocybin for U.S. military Veterans with severe treatment-resistant depression - 12-month data from an open-label pilot study. - Ellis S; Bostian C; Donnelly A; Feng W; Eisen K; Lean M; Conlan E; Ostacher M; Aaronson S; Suppes T. (2025)

Clinical conceptualisation of PTSD in psilocybin treatment: disrupting a pre-determined and over-determined maladaptive interpretive framework. - Modlin NL; Williamson V; Maggio C; Stubley J; Kirlic N; Cleare A; Rucker J. (2025)

"Wood-lover paralysis": Describing a toxidrome with symptoms of weakness caused by some lignicolous "wood-loving" Psilocybe mushrooms. - Beck SA; Barlow C; Engel L; Barratt MJ. (2025)

Psilocybin With Intracranial Neural Sensing - Joshua Woolley; MD; PhD (ClinicalTrials.gov, 2025)

Meditation and psychedelics facilitate similar types of mystical, psychological, and philosophical-existential insights predictive of wellbeing: A qualitative-quantitative approach - Jylkkä J. (PsyArXiv, 2025)

Human neuroimaging: fMRI. - Wall MB; Carhart-Harris RL. (2025)

Enhanced meaning in life following psychedelic use: converging evidence from controlled and naturalistic studies. - Roseby W; Kettner H; Roseman L; Spriggs MJ; Lyons T; Peill J; Giribaldi B; Erritzoe D; Nutt DJ; Carhart-Harris RL. (2025)

Classic Psychedelics in Pain Modulation: Mechanisms, Clinical Evidence, and Future Perspectives. - Czopek A; Jończyk J; Fryc M; Kluzik D; Zagórska A. (2025)

Meditation and psychedelics facilitate similar types of mystical, psychological, and philosophical-existential insights predictive of wellbeing: A qualitative-quantitative approach (PsyArXiv, 2025)

Low-Income Group Psilocybin Assisted Therapy for Depression: A Feasibility Study - Matthew Hicks (ClinicalTrials.gov, 2025)

Optimizing Microdosing and Meditation - National University of Natural Medicine (ClinicalTrials.gov, 2025)

Geographical Differences in Self-Reported Past 12-Month Drug Use: Results from the NDEWS Rapid Street Reporting, 2021-2023. - Won NY; Wang A; Athay R; Striley CW; Cottler LB. (2025)

Psilocybin's acute and persistent brain effects: a precision imaging drug trial. - Subramanian S; Reneau TR; Perry D; Chacko R; Laumann TO; Flavin K; Horan C; Schweiger J; Metcalf N; Lenze EJ; Snyder AZ; Dosenbach NUF; et al. (2025)

Leveraging psychedelic neuroscience to boost human creativity using artificial intelligence. - Ross BM. (2025)

Clade III Synthases Add Cyclic and Linear Terpenoids to the Psilocybe Metabolome. - Zschoche N; Schober S; Walther K; Chadeayne AR; Gressler M; Bartram S; O'Connor SE; Hoffmeister D. (2025)

Psychedelics in the Treatment of Neurologic and Psychiatric Disorders: Coincidence or a New Point of View. - Lashgari NA; Khalaji M; Rana P; Badrabadi F; Rahnama M; Nasoori H; Momeni Roudsari N; Khosravi Nia MM; Shafaroodi H. (2025)

Effects of Psilocybin on Mouse Brain Microstructure. - Frautschi PC; Singh AP; Stowe NA; Grady SM; Zahid Z; Banks MI; Yu JJ. (2025)

Self-inflicted transorbital intracranial foreign body following ingestion of hallucinogenic psilocybin mushrooms. - Blanton AM; Parikh P; Zhou S; Mohamed M; Ufret-Vincenty RL; Mancini R. (2025)

In vitro assessment of psilocin for CYP-dependent drug-drug interaction potential using rapid luminescent assays - Cali James (Drug Metabolism and Pharmacokinetics, 2025)

Correction to: Unraveling psilocybin's therapeutic potential: behavioral and neuroplasticity insights in Wistar-Kyoto and Wistar male rat models of treatment-resistant depression. - Kolasa M; Nikiforuk A; Korlatowicz A; Solich J; Potasiewicz A; Dziedzicka-Wasylewska M; Bugno R; Hogendorf A; Bojarski A; Faron-Górecka A (Psychopharmacology, 2025)

The therapeutic effects of psychedelics for opioid use disorder: A systematic review of clinical studies. - Weleff J; Pulido-Saavedra A; Aghaei AM; Ing K; Arakelian M; Fontenele R; Nero N; Barnett BS; Anand A; Bassir Nia A; Angarita GA (Psychiatry research, 2025)

Innovation and inequity in psychedelic research at the Mayo Clinic. - Klim C; VanDreese B; Meyerhoefer T; Breitinger S (History of psychiatry, 2025)

There's More Than One Way to Bring Health Back: Divergent Effects of Psilocybin and Escitalopram Treatment on Emotional Brain Function in Depression. - Fonzo GA; Doss MK; Nemeroff CB. (2025)

Role of endogenous serotonin in psychedelic-like effects of psilocybin in mice. - Erkizia-Santamaría I; Martínez-Álvarez N; Salinas-Novoa L; Meana JJ; Ortega JE. (2025)

Psychedelic fungi. - Slot J; Hoffmeister D. (2025)

Long-term benefits of single-dose psilocybin in depressed patients with cancer. - Agrawal M; Roddy K; Jenkins B; Leeks C; Emanuel E. (2025)

Neurocognitive effects of psilocybin: A systematic and comprehensive review of neuroimaging studies in humans. - Berkovitch L; Fauvel B; Preller KH; Gaillard R. (2025)

Exploring Public Sentiments of Psychedelics Versus Other Substances: A Reddit-Based Natural Language Processing Study. - Biba B; O'Shea BA. (2025)

Converging pathways: shared brain circuitry engaged by monoaminergic antidepressants, ketamine and psilocybin - Joseph K; Collins J; Genovese T; Maxwell M; Lieberman JA; Osten P. (bioRxiv, 2025)

Exploration of Synaptotrophic Effects of Psilocybin in Opioid Use Disorder (OUD) - Yale University (ClinicalTrials.gov, 2025)

Understanding the Psychological Effects of Psilocybin and 3,4-Methylenedioxymethamphetamine in a Non-Clinical Population - Fitzgerald PB; Webb SL; Denning NC; Dowie T; Schweickle MM; Modak A; Chan G; Knight J; Waldron M; Gainsford K; Hawkes H; Zammit S; et al. (medRxiv, 2025)

Patients' Attitudes Toward Hallucinogenic and Non-Hallucinogenic Psilocybin for Mental Health Treatment. - Abboud A; Schiebrel C; Nahhas RW; Durkin S; Hua K; Redding H; Gainer D. (2025)

The Selective Serotonin 5-HT2A Receptor Agonist (S)-3-(2,5-Dimethoxy-4-(trifluoromethyl)phenyl)piperidine (LPH-5) Induces Persistent and Robust Antidepressant-Like Effects in Rodents. - Jensen AA; Cecchi CR; Hibicke M; Bach AH; Kaadt E; Märcher-Rørsted E; Nichols CD; Elfving B; Kristensen JL. (2025)

Role of the Serotonin 2A Receptor in Psilocybin-induced Altered States of Consciousness (PDR-Study) - University Hospital; Basel; Switzerland (ClinicalTrials.gov, 2025)

Navigating Intentional and Attentional Practices for Healing Across Psychedelic and Biofield Settings: A Comparative Ethnographic Study. - Paracha N. (2025)

Effects of serotonergic psychedelics on synaptogenesis and immediate early genes expression - comparison with ketamine, fluoxetine and lithium. - Vella Y; Syrová K; Petrušková A; Koutrouli I; Kútna V; Pala J; Šíchová K; Nikolič M; Mazoch V; Jurok R; Kuchař M; Bendová Z; et al. (2025)

Attitudes Toward Psychedelic Treatments by Individuals With Histories of Substance Use or Psychiatric Disorders: A Survey Study. - Prostko S; Wu A; Maddams S; Szpak V; Rosenblum N; Hilt LM; Suzuki J. (2025)

Pharmacologic interventions for alcohol use disorder. - Menge J; Evitt B. (2025)

Psilocybin-enhanced fear extinction linked to bidirectional modulation of cortical ensembles. - Rogers SA; Heller EA; Corder G. (2025)

Psilocybin mitigates behavioral despair and cognitive impairment in treatment-resistant depression model using wistar kyoto rats. - Wang Z; Robbins B; Zhuang R; van Bruggen R; Sandini T; Li XM; Zhang Y. (2025)

Therapeutic emergence of dissociated traumatic memories during psilocybin treatment for anorexia nervosa. - Peck SK; Brewerton TD; Fisher H; Trim J; Shao S; Modlin NL; Kim J; Finn DM; Kaye WH. (2025)

The Potential Role of Psilocybin in Traumatic Brain Injury Recovery: A Narrative Review. - Palmer C; Ferber AT; Greenwald BD. (2025)

Race and Gender Differences in the Moderating Relationship of Psychedelics on Stigma and Distress. - Viña SM. (2025)

Psilocybin and psilocin regulate microglial immunomodulation and support neuroplasticity via serotonergic and AhR signaling. - Laabi S; LeMmon C; Vogel C; Chacon M; Jimenez VM. (2025)

Adverse reactions among psychedelic users: Norwegian validation of the Challenging Experience Questionnaire. - Andersen KAA; Holmøy B; Kvam TM; Johnson MW. (2025)

Psilocybin-facilitated Smoking Cessation Treatment: A Pilot Study - Johns Hopkins University (ClinicalTrials.gov, 2025)

An Investigation of Strategies to Understand and Optimize the Antidepressant Effects of Psilocybin (The OPTIMIZE Study) - Charles Raison (ClinicalTrials.gov, 2025)

Clinical pharmacology. - Vogt SB; Liechti ME. (2025)

Ergotamine enhances circadian amplitude and diurnally mitigates nitroglycerin-induced mechanical hypersensitivity. - Han C; Baek H; Lim JY; Kim E; Tran CK; Freeman E; Chen Z; Yoo SH; Burish MJ. (2025)

[Psilocybin in the setting of treatment-resistant unipolar depression: A case report]. - Dumenil M; Cordova G; El-Hage W. (2025)

Age and cannabis co-use moderate experience and perceived benefits of psilocybin - Hooper J; Williams S; Mueller R; Hutchison K. (PsyArXiv, 2025)

Age and cannabis co-use moderate experience and perceived benefits of psilocybin (PsyArXiv, 2025)

Lessons learned from the regulatory alignment in ketamine, esketamine and arketamine clinical trials: A cross-sectional analysis of protocols from ClinicalTrials.gov. - Swieczkowski D; Kwaśny A; Sadko K; Pruc M; Gaca Z; Szarpak L; Cubała WJ. (2025)

Separate or inseparable? Serotonin and dopamine system interactions may underlie the therapeutic potential of psilocybin for anorexia nervosa. - McCoy K; Reed F; Conn K; Foldi CJ. (2025)

Additions to the Inocybe sect. Leptocybe (Agaricales) in China: new species from tropical rainforests, new geographical distributions, and toxin detection. - Gao JL; Wu XP; Zhou YL; Yu WJ; Fan YG. (2025)

Can the gut-brain axis provide insight into psilocybin's therapeutic value in reducing stress? - Kit A; Conway K; Makarowski S; O'Regan G; Allen J; Shultz SR; Bodnar TS; Christie BR. (2025)

Psychedelic-like effects induced by 2,5-dimethoxy-4-iodoamphetamine, lysergic acid diethylamide, and psilocybin in male and female C57BL/6J mice. - McGriff SA; Hecker JC; Maitland AD; Partilla JS; Baumann MH; Glatfelter GC. (2025)

Under Pressure: Stronger depressive symptoms are associated with more positive expectations towards experimental treatments - Basedow LA; Lottes L; Falkenberg I; Vogelbacher C; Yildiz C. (PsyArXiv, 2025)

Consciousness and Psilocybin Effects on Well-Being (The CoPE Study): Pilot Phase - University of Wisconsin; Madison (ClinicalTrials.gov, 2025)

Under Pressure: Stronger depressive symptoms are associated with more positive expectations towards experimental treatments (PsyArXiv, 2025)

The Relationships Between Healthcare Access, Gender, and Psychedelics and Their Effects on Distress. - Viña SM. (2025)

Aesthetic quality of psychedelic experience is linked to insight and psychological outcomes. - Hooper JF; Gyongyosi EL; Hutchison KE; Mueller RL. (2025)

The Intersection of Psychedelics and Sleep: Exploring the Impacts on Sleep Architecture, Dream States, and Therapeutic Implications. - Zhai H; Wang H; Li H; Wang X. (2025)

Pathway engineering for the biosynthesis of psychedelics. - Abrahms ZN; Sen AK; Jones JA. (2025)

Investigating the Role of Serotonin in the Mechanism of Action of Psilocybin in Patients With Major Depressive Disorder - Icahn School of Medicine at Mount Sinai (ClinicalTrials.gov, 2025)

Serotonergic psychedelics for depression: A comprehensive overview. - Wingert AM; Agnorelli C; Peill J; Reed S; Nutt DJ; Erritzoe D. (2025)

The pharmacological treatment of anxiety in people with eating disorders: A systematic review. - Morris R; Keeler J; Treasure J; Himmerich H. (2025)

Psilocybin and Obsessive-Compulsive Disorder: Exploring New Therapeutic Horizons. - Yang L; Li H; Wang X; Wang X. (2025)

A Phase 2a, Placebo-Controlled Randomized, Double-Blind Trial to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Psilocybin Oral Solution in Adults With Generalized Anxiety Disorder - Queen's University (ClinicalTrials.gov, 2025)

Psilocybin-induced modulation of visual salience processing - Muller S; Cavanna F; de la Fuente LA; Bruno N; D’Amelio TA; Pallavicini C; Tagliazucchi E. (bioRxiv, 2025)

Set and setting of psychedelics for therapeutic use in psychiatry: A systematic review. - Estric C; Duron T; Kabani S; Lopez-Castroman J. (2025)

The effect of psychedelic microdosing on animal behavior: A review with recommendations for the field. - Syed OA; Petranker R; Tsang B. (2025)

Non-hallucinogenic psychedelics for mood and anxiety disorders: A systematic review. - Chen MJQ; Chen-Li D; Chisamore N; Husain MI; Di Vincenzo JD; Mansur RB; Phan L; Johnson D; McIntyre RS; Rosenblat JD. (2025)

Race/ethnicity moderates the associations between lifetime psilocybin use and opioid use disorder. - Jones G. (2025)

Reduced Brain Responsiveness to Emotional Stimuli With Escitalopram But Not Psilocybin Therapy for Depression. - Wall MB; Demetriou L; Giribaldi B; Roseman L; Ertl N; Erritzoe D; Nutt DJ; Carhart-Harris RL. (2025)

The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder - Sharmin Ghaznavi (ClinicalTrials.gov, 2025)

Psilocybin Mitigates Behavioral Despair and Cognitive Impairment in Treatment-resistant Depression Model using Wistar Kyoto Rats - Wang Z; Robbins B; Zhuang R; Bruggen Rv; Sandini T; Li X; Zhang Y. (Research Square, 2025)

A protocol for a scoping review of variations among psychedelic interventions for psychological suffering associated with the end-of-life. - Kratina S; Strike C; Schwartz R; Nayfeh A; Jopling S; Lo C; Rush B. (2025)

The Role of Touch in Psychedelic Therapy: Perspectives From a Survey of Practitioners in Research Settings. - Bender DA; Nayak SM; Siegel JS; Hellerstein DJ; Ercal BC; Lenze EJ. (2025)

A landscape analysis of psychedelic retreat organizations advertising online. - Neitzke-Spruill L; Beit CS; Robinson JO; Singh N; Kambala S; Ramesh R; McGuire AL. (2025)

Cross-Species Evidence for Psilocin-Induced Visual Distortions: Apparent Motion Is Perceived by Both Humans and Rats. - Vejmola Č; Šíchová K; Syrová K; Janečková L; Koudelka V; Tesař M; Nikolič M; Viktorinová M; Tylš F; Korčák J; Viktorin V; Kelemen E; et al. (2025)

Pharmacokinetics (PK) of psilocybin and psilocin in plasma following intravenous administration of psilocin and oral administration of psilocybin to male beagle dogs - de Lannoy Ines; Magomedova Lilia; Izhakova Julia; de Rivera Christina; Lanthier James; Atkinson Jason; Higgins Guy A.; Slassi Malik; Araujo Joseph A. (Journal of Pharmacological and Toxicological Methods, 2025)

The intensity of the psychedelic experience is reliably associated with clinical improvements: A systematic review and meta-analysis. - Romeo B; Kervadec E; Fauvel B; Strika-Bruneau L; Amirouche A; Bezo A; Piolino P; Benyamina A (Neuroscience and biobehavioral reviews, 2025)

Dose-dependent changes in global brain activity and functional connectivity following exposure to psilocybin: a BOLD MRI study in awake rats. - Fuini E; Chang A; Ortiz RJ; Nasseef T; Edwards J; Latta M; Gonzalez E; Woodward TJ; Axe B; Maheswari A; Cavallaro N; Bradshaw HB; et al. (2025)

Divergent Effects of Psilocybin for 2 Patients Participating in a Psilocybin-assisted Cognitive Behavioral Therapy Trial for Major Depressive Disorder. - Weintraub MJ; Miklowitz DJ; Jeffrey JK. (2025)

From molecules to meaning: unpacking the antidepressant mechanisms of psychedelic drugs. - Acero VP; Flatt TA; Gooch PM; Gaughan SJ; Levin AW; Davis AK (Expert review of clinical pharmacology, 2025)

Premorbid characteristics of the SAPAP3 mouse model of obsessive-compulsive disorder: behavior, neuroplasticity, and psilocybin treatment. - Lazar M; Brownstien M; Botvinnik A; Shevakh C; Shahar O; Lifschytz T; Lerer B. (2025)

Untargeted analysis of psilocybin and non-psilocybin mushrooms using liquid chromatography quadrupole time of flight mass spectrometry. - Islam S; Liden T; Goff R; Schug KA. (2025)

Calcium Activation Mechanism of a Noncanonical Aromatic L-Amino Acid Decarboxylase from Psilocybin Mushroom - Wang Y; Li T; Reynolds E; Wang Z; Torrens-Spence M; Weng J. (Research Square, 2025)

Dissociable effects of psilocybin and escitalopram for depression on processing of musical surprises. - Harding R; Singer N; Wall MB; Hendler T; Erritzoe D; Nutt D; Carhart-Harris R; Roseman L. (2025)

Treatment With Psilocybin for Chronic Neuropathic Pain and Depression (TRANSCEND): An Open-Label Clinical Trial - Centre for Addiction; Mental Health (ClinicalTrials.gov, 2025)

Exploring Factors Affecting Psychological Flexibility After Psychedelic Experiences. - Romeo B; Kervadec E; Fauvel B; Strika-Bruneau L; Amirouche A; Verroust V; Piolino P; Benyamina A (Journal of psychoactive drugs, 2025)

The phenomenology of psilocybin: transformative insights for research and clinical practice. - Metastasio A; Prevete E; Venturini S; Garofalo A; Cecconello B; De Pisapia N; Corazza O. (2025)

Psilocybin-assisted psychotherapy as a rapid-acting treatment for cancer-related depression and anxiety: Evidence from a network meta-analysis. - Swieczkowski D; Kwaśny A; Pruc M; Gaca Z; Szarpak L; Cubała WJ. (2025)

Editorial: Beyond psilocybin: exploring the clinical potential of alternative and novel psychedelics. - Williams ML; Rudin D; Schmid Y; von Salm J. (2025)

5-HT2A receptors: Pharmacology and functional selectivity. - Cummins BR; Billac GB; Nichols DE; Nichols CD. (2025)

Incremental efficacy systematic review and meta-analysis of psilocybin-for-depression RCTs. - Borgogna NC; Owen T; Petrovitch D; Vaughn J; Johnson DAL; Pagano LA; Aita SL; Hill BD. (2025)

Probing the functional magnetic resonance imaging response to psilocybin in functional neurological disorder (PsiFUND): study protocol - Butler M; Bird C; Maggio C; Durden A; Modlin N; Campbell-Coker K; Edwards M; Pick S; Millman LM; Lowery E; Bhagavan C; Kanaan R; et al. (Wellcome Open Res, 2025)

Evaluating the effectiveness of psilocybin in alleviating distress among cancer patients: A systematic review. - Lapid MI; Pagali SR; Randall AL; Donovan KA; Bronars CA; Gauthier TA; Bock J; Lim SD; Carey EC; Sokolowski E; Ulrich AM; Hassett LC; et al. (2025)

Comprehensive analysis of 42 psilocybin-producing fungal strains reveals metabolite diversity and species-specific clusters. - Cohen J; Sulimani L; Procaccia S; Lerenthal Y; Milay L; Taran I; Shapira A; Meiri D. (2025)

Rapid and sustained antidepressant effects of vaporized N,N-dimethyltryptamine: a phase 2a clinical trial in treatment-resistant depression. - Falchi-Carvalho M; Palhano-Fontes F; Wießner I; Barros H; Bolcont R; Laborde S; Ruschi B Silva S; Montanini D; C Barbosa D; Teixeira E; Florence-Vilela R; Almeida R; et al. (2025)

The Rise of Psilocybin Use in the United States: A Multisource Observational Study. - Rockhill KM; Black JC; Ladka MS; Sumbundu KB; Olsen HA; Jewell JS; Hunt J; Wolf RC; Nerurkar K; Dart RC; Monte AA. (2025)

Effects of psychedelics on human oscillatory brain activity. - Godfrey K; Luan LX; Timmermann C. (2025)

Psychedelics and substance use disorder treatment. - DuPont CM; Johnson MW. (2025)

Development of a PBPK model of psilocybin/psilocin from Psilocybe cubensis (magic mushroom) in mice, rats, and humans. - Thaoboonruang N; Lohitnavy O; Ya K; Lohitnavy M. (2025)

In Vitro Psilocybin Synthesis by Co-Immobilized Enzymes. - Schäfer T; Sherwood A; Kirkland T; Krüger T; Worbs J; Kniemeyer O; Gressler M; Hoffmeister D. (2025)

Comparative Efficacy and Functional Outcomes of Psychedelic-Assisted Therapies in Treatment-Resistant Depression: A Systematic Review of Recent Clinical Trials. - Mimms C; Sotelo K; Khaliq AS. (2025)

Roadmap for Equitable Access and Responsible Use of Psilocybin-Assisted Psychotherapy in Palliative Care. - Dorval M; Chang SL; Farzin H; Nguyen O; Stephan JF; Tapp D; Deschamps P; Joly Y; Moureaux F; Foxman R; Masse-Grenier M; Fallu JS; et al. (2025)

Psilocybin and ketamine affect novel neuropeptides gene expression in the rat hypothalamus. - Pałasz A; Pukowiec M; Bogus K; Suszka-Świtek A; Filipczyk Ł; Mordecka-Chamera K; Worthington JJ; Sygidus M; Wojtas A; Bysiek A; Gołembiowska K. (2025)

Regulatory Alignment of Psilocybin Clinical Trials in Major Depressive Disorder on ClinicalTrials.gov: A Cross-Sectional Analysis. - Swieczkowski D; Kwaśny A; Pruc M; Gaca Z; Szarpak L; Cubała WJ. (2025)

A Phase 2a, Open-label, Pilot Study to Assess the Safety and Efficacy of Psilocybin Administration in Concert With Psychotherapy Among Adult Patients With Fibromyalgia - Kevin Boehnke (ClinicalTrials.gov, 2025)

Psilocybin biosynthesis enhancement through gene source optimization. - Keller MR; McKinney MG; Sen AK; Guagliardo FG; Hellwarth EB; Islam KN; Kaplan NA; Gibbons WJ; Kemmerly GE; Meers C; Wang X; Jones JA. (2025)

Psilocybin has a narrow therapeutic window as an antidepressant treatment. - Seillier L; Čechová B; Seillier A; Šlamberová R. (2025)

Psilocybin-Assisted suppoRtive psychoTherapy IN the treatment of prolonged Grief (PARTING) trial: protocol for an open-label pilot trial for cancer-related bereavement. - Beesley VL; Kennedy TJ; Maccallum F; Ross M; Harvey R; Rossell SL; Sarris J; Perkins D; Neale RE; Bennett-Levy J; Johnson S; Beebe H; et al. (2025)

Efficacy and safety of psilocybin for the treatment of substance use disorders: A systematic review. - Meshkat S; Malik G; Zeifman RJ; Swainson J; Balachandra K; Reichelt AC; Zhang Y; Burback L; Winkler O; Greenshaw A; Vermetten E; Mayo LM; et al. (2025)

Psilocin alleviates acute itch in mice: possible involvement of 5-HT2A receptors and kynurenine pathway. - Afrooghe A; Ahmadi E; Lesani A; Mehranjani MS; Elahi M; Babaei M; Shayan M; Shafaroodi H; Jafari RM; Foroumadi A; Manavi MA; Dehpour AR. (2025)

The Role of Personal Experience for the Therapeutic Attitude in the Context of Substance-assisted Therapy Training - Felix Mueller (ClinicalTrials.gov, 2025)

Assessing the potential cardiovascular risk of microdosing the psychedelic LSD in mice - Effinger DP; Schalk SS; King JL; Strong JR; O’Connell CK; Calderon JR; McCorvy JD; Thompson SM. (bioRxiv, 2025)

PsiConnect: A Multimodal Neuroimaging Study of Psilocybin-Induced Changes in Brain and Behaviour - Novelli L; Stoliker D; Barta T; Greaves MD; Chopra S; Jackson J; Kwee J; Williams ML; Razi A. (bioRxiv, 2025)

Acute Dose-dependent Effects of DMT-bolus Applications in Healthy Subjects: A Placebo-controlled Cross-over Study (DMT BDR-Study). - University Hospital; Basel; Switzerland (ClinicalTrials.gov, 2025)

Psilocybin as a Tool in the Management of Palliative Care: An Historical, Pharmacological, and Clinical Approach - Turizo Smith AD; Botero Jsramillo N; Berrio Cuartas DM. (Preprints.org, 2025)

Functional and structural characterization of the human indolethylamine N-methyltransferase through fluorometric, thermal and computational docking analyses. - Ardini M; Angelucci F; Rea F; Paluzzi L; Gabriele F; Palerma M; Di Leandro L; Ippoliti R; Pitari G. (2025)

Targeting Phantom Pain with Psilocybin: Toward Integration with Adaptive Sensory Technologies. - Kargbo RB. (2025)

Exploring psilocybin's role in mental health and palliative medicine: a path to improved well-being. - Umbacia MA; Leon MX; Quintero JM; Castro LM; Paez V; Dodd S; Bustos RH. (2025)

Psilocybin-assisted Interpersonal Therapy for Depression - University of Otago (ClinicalTrials.gov, 2025)

The Emergence of Psilocybin in Psychiatry and Neuroscience. - Omidian H; Omidian A. (2025)

A multi-institutional investigation of psilocybin’s effects on mouse behavior - Lu OD; White K; Raymond K; Liu C; Klein AS; Green N; Vaillancourt S; Gallagher A; Shindy L; Li A; Wallquist K; Li R; et al. (bioRxiv, 2025)

Psilocybin therapy for mood dysfunction in Parkinson's disease: an open-label pilot trial. - Bradley ER; Sakai K; Fernandes-Osterhold G; Szigeti B; Ludwig C; Ostrem JL; Tanner CM; Bock MA; Llerena K; Finley PR; O'Donovan A; Zuzuarregui JRP; et al. (2025)

The compulsive eating paradigm: can psychedelics help in treating obesity? - Ammineni D; Park R. (2025)

Letter to the editor: Comments on 'Striking long-term beneficial effects of single-dose psilocybin and psychedelic mushroom extract in the SAPAP3 rodent model of OCD-like excessive self-grooming' by Brownstien et al. (2024). - Gattuso JJ; Wilson C; Hannan AJ; Renoir T. (2025)

Potential therapeutic effects of psychedelics in small doses: Is there a role for microdosing in psychiatry? - Totomanova I; Haijen ECHM; Hurks PPM; Ramaekers JG; Kuypers KPC. (2025)

Neuroplasticity and psychedelics: A comprehensive examination of classic and non-classic compounds in pre and clinical models. - Agnorelli C; Spriggs M; Godfrey K; Sawicka G; Bohl B; Douglass H; Fagiolini A; Parastoo H; Carhart-Harris R; Nutt D; Erritzoe D. (2025)

Psilocybin's lasting action requires pyramidal cell types and 5-HT2A receptors. - Shao LX; Liao C; Davoudian PA; Savalia NK; Jiang Q; Wojtasiewicz C; Tan D; Nothnagel JD; Liu RJ; Woodburn SC; Bilash OM; Kim H; et al. (2025)

Psilocybin mushrooms (“Magic Mushrooms”) (Organization of Teratology Information Specialists (OTIS), Brentwood (TN), 2025)

A Rapid Review of Psychedelic-Assisted Therapy in the Context of Palliative Care. - Miller M; Meyers M; Martin A; Napolitano S; Dorsen C; Penn A; Rosa WE (Journal of hospice and palliative nursing: JHPN: the official journal of the Hospice and Palliative Nurses Association, 2025)

Psilocin, A Psychedelic Drug, Exerts Anticonvulsant Effects Against PTZ- and MES-Induced Seizures in Mice via 5-HT1A and CB1 Receptors: Involvement of Nitrergic, Opioidergic, and Kynurenine Pathways. - Balabandian M; Manavi MA; Lesani A; Mohammad Jafari R; Shafaroodi H; Heidari N; Mirnajafi-Zadeh J; Foroumadi A; Afrooghe A; Dehpour AR. (2025)

Psilocybin Dispensaries and Online Health Claims in Canada. - Matsukubo J; Dickson S; Xiao J; Friesen EL; Solmi M; Fiedorowicz JG; Fischer B; Myran DT. (2025)

Psilocybin Dispensaries and Advertising-Buyer Beware. - Hutson PR. (2025)

De Novo Biosynthesis of Antidepressant Psilocybin in Escherichia coli. - Huang Z; Yao Y; Di R; Zhang J; Pan Y; Liu G. (2025)

[Treatment with psychedelics: potential benefits in Parkinson's disease]. - Penzenstadler L; Baudois S; Lingenberg A; Catalano Chiuvé S; Tomkova E; Fleury V. (2025)

The Afterglow Inventory (AGI): Validation of a new instrument for measuring subacute effects of classic serotonergic psychedelics. - Majić T; Schmidt TT; Gröticke A; Gasser P; Richards WA; Riemer TG; Evens R. (2025)

Effects of a single dose of psilocybin on diet-induced weight loss in obese mice - Keenan R; Haque R; Jin X; Mustafa T; Homman-Ludiye J; Elysee K; Wee ZS; Simonds S; Foldi C; Cowley M. (Research Square, 2025)

Utilizing Psychedelics to Enhance Well-Being: A Systematic Review. - Thomson S; Thomacos N. (2025)

Sporadic use of classic psychedelics and neuropsychological performance: A cross-sectional analysis. - Reiche S; Hirschfeld T; Gröticke AL; Traub M; Hafiz NJ; Haas R; Sedlaczek L; Ortlieb L; Leistenschneider G; Basedow LA; Lohse A; Bermpohl F; et al. (2025)

Psilocybin for Enhanced Analgesia in Chronic nEuropathic PAIN - Unity Health Toronto (ClinicalTrials.gov, 2025)

Visual Hallucinations in Serotonergic Psychedelics and Lewy Body Diseases (PsyArXiv, 2025)

Visual Hallucinations in Serotonergic Psychedelics and Lewy Body Diseases - Heller NH; Barrett FS; Buchborn T; Collerton D; Dupuis D; Halberstadt AL; Jardri R; Noorani TN; Preller KH; Taylor J; Waters F; Winston B; et al. (PsyArXiv, 2025)

Do undergraduates' views of psychedelics relate to the context for psychedelic use? - Petrovitch D; Van Allen J; Mitchell SM; Littlefield AK. (2025)

Ayahuasca in the treatment of the consequences of chronic childhood sexual abuse in a religious community - Turkia M. (PsyArXiv, 2025)

Direct Comparison of Altered States of Consciousness Induced by LSD, Psilocybin, and DMT in a Randomized, Placebo-controlled, Cross-over Trial in Healthy Participants (LPD-Study) - University Hospital; Basel; Switzerland (ClinicalTrials.gov, 2025)

Ayahuasca in the treatment of the consequences of chronic childhood sexual abuse in a religious community (PsyArXiv, 2025)

The effect of low-dose psilocybin on brain neurotransmission and rat behavior. - Bysiek A; Wojtas A; Szpręgiel I; Wawrzczak-Bargieła A; Maćkowiak M; Gołembiowska K. (2025)

Existing evidence for the use of psychedelics in patients with cancer and other serious illness: A narrative review. - Bires J. (2025)

Intravenous psilocybin induces dose-dependent changes in functional network organization in rat cortex. - Silverstein BH; Kolbman N; Nelson A; Liu T; Guzzo P; Gilligan J; Lee U; Mashour GA; Vanini G; Pal D. (2025)

Pharmacokinetics of Psilocybin: A Systematic Review. - Meshkat S; Al-Shamali H; Perivolaris A; Tullu T; Zeifman RJ; Zhang Y; Burback L; Winkler O; Greenshaw A; Husain MI; C Reichelt A; Vermetten E; et al. (2025)

Comparing Antidepressant Effects of Psilocybin-Assisted Psychotherapy in Individuals That Were Unmedicated at Initial Screening Versus Individuals Discontinuing Medications for Study Participation: Comparaison des effets antidépresseurs de la psychothérapie assistée par la psilocybine (PAP) chez les personnes non médicamentées à la sélection initiale et les personnes ayant arrêté les médicaments pour participer à l'étude. - Chisamore N; Kaczmarek ES; Doyle Z; Johnson DE; Weiglein G; Meshkat S; Brudner RM; Blainey MG; Riva-Cambrin J; McIntyre RS; Rosenblat JD. (2025)

Is there room for ethics of authenticity in psilocybin research? - Jerotic S. (2025)

Classic Psychedelics for the Treatment of Depression: Potential Benefits and Challenges. - Ghaznavi S; Richter SG. (2025)

Anhedonia: Current and future treatments. - Serretti A. (2025)

LPS-Induced Liver Inflammation Is Inhibited by Psilocybin and Eugenol in Mice. - Robinson GI; Gerasymchuk M; Zanikov T; Gojani EG; Asghari S; Groves A; Haselhorst L; Nandakumar S; Stahl C; Cruz C; Cameron M; Zahoruiko Y; et al. (2025)

Structural basis for psilocybin biosynthesis. - Meng C; Guo W; Xiao C; Wen Y; Zhu X; Zhang Q; Liang Y; Li H; Xu S; Qiu Y; Chen H; Lin WJ; et al. (2025)

The effects of psilocybin therapy versus escitalopram on cognitive bias: A secondary analysis of a randomized controlled trial - Henry J; Giribaldi B; Nutt DJ; Erritzoe D; Carhart-Harris R; Lyons T. (medRxiv, 2025)

Is there a place for psychedelics in sports practice? - Portes MAM; Werle I; Bertoglio LJ. (2025)

Psychedelic Drugs in Mental Disorders: Current Clinical Scope and Deep Learning-Based Advanced Perspectives. - Kim SH; Yang S; Jung J; Choi J; Kang M; Joo JY. (2025)

Synthesis and In Vitro Profiling of Psilocin Derivatives: Improved Stability and Synthetic Properties. - Eklund J; Bremberg U; Larsson J; Torkelsson E; Wennerberg J; Zandelin S; Odell LR. (2025)

Polysubstance Use Profiles Among the General Adult Population, United States, 2022. - Rockhill KM; Black JC; Iwanicki J; Abraham A. (2025)

An 8-week Phase 2 Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of Psilocybin-assisted-psychotherapy in Adults With Cannabis Use Disorder: A Proof-of-Concept Study - McMaster University (ClinicalTrials.gov, 2025)

Molecular Imaging Study of Harmine/DMT: a Basic Research Approach - Insel Gruppe AG; University Hospital Bern (ClinicalTrials.gov, 2025)

Psilocybin in Alcohol Use Disorder With Comorbid Depression - Centre Hospitalier Universitaire de Nīmes (ClinicalTrials.gov, 2025)

Preliminary safety and effectiveness of psilocybin-assisted therapy in adults with fibromyalgia: an open-label pilot clinical trial. - Aday JS; McAfee J; Conroy DA; Hosanagar A; Tarnal V; Weston C; Scott K; Horowitz D; Geller J; Harte SE; Pouyan N; Glynos NG; et al. (2025)

A Randomized, Placebo-controlled Trial of Psychedelic-assisted Psychotherapy With Single Dose Psilocybin for Frontline Clinicians Experiencing COVID-related Symptoms of Depression and Burnout - University of Washington (ClinicalTrials.gov, 2025)

The psychedelic psilocybin and light exposure have similar and synergistic effects on gene expression patterns in the visual cortex. - Harari R; Getselter D; Elliott E. (2025)

Exploring the potential of psychedelic-assisted psychotherapy for moral injury: A scoping review. - Kurkova V; Winkler O; Greenshaw A; Jetly R; Swainson J; Lodewyk K; Saghafi P; Dennett E; Burback L. (2025)

A Modern Overview of the Potential Therapeutic Effects of Psilocybin in the Treatment of Depressive Disorders, Treatment-Resistant Depression, and End-of-Life Distress. - Dino F. (2025)

IUPHAR Article: Psilocybin induces long-lasting effects via 5-HT2A receptors in mouse models of chronic pain. - Koseli E; Buzzi B; Honaker T; Rakholia Y; Lewis M; Gaines-Smith M; Jaster AM; Gonzalez-Maeso J; Damaj MI. (2025)

Therapeutic Potential of Psilocybin for Treating Neuropsychiatric Long COVID Symptoms: A Reddit Investigation. - Bobak L; Dorney I; Kovacevich A; Barnett BS. (2025)

Psilocybin-assisted therapy for relapse prevention in alcohol use disorder: a phase 2 randomized clinical trial. - Rieser NM; Bitar R; Halm S; Rossgoderer C; Gubser LP; Thévenaz M; Kreis Y; von Rotz R; Nordt C; Visentini M; Moujaes F; Engeli EJE; et al. (2025)

Effects of Psilocybin in Advanced-Stage Cancer Patients With Anxiety - Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center (ClinicalTrials.gov, 2025)

Lifetime classic psychedelic use and headaches: A cross-sectional study. - Bjurenfalk Z; Cosmo A; Simonsson O; Ran C. (2025)

Psychedelics and autobiographical memory - Six open questions - Kangaslampi S; Lietz MP. (PsyArXiv, 2025)

Psychedelics Align Brain Activity with Context - Stoliker D; Novelli L; Khajehnejad M; Biabani M; Greaves MD; Barta T; Williams M; Chopra S; Bazin O; Simonsson O; Chambers R; Barrett F; et al. (bioRxiv, 2025)

Lasting effect of psilocybin on sociability can be blocked by DNA methyltransferase inhibition - Song C; Chang T; Buchborn T; Knöpfel T. (bioRxiv, 2025)

Psychedelics and autobiographical memory - Six open questions (PsyArXiv, 2025)

Revealing Changes in Linear and Nonlinear Functional Connectivity After Psilocybin and Escitalopram Treatment in Patients with Depression - Quah S; Glick C; Roseman L; Pasquini L; Carhart-Harris R; Saggar M. (bioRxiv, 2025)

Psilocybin for disorders of consciousness: A case-report study. - Cardone P; Núñez P; Alnagger NLN; Martial C; van der Lande GJM; Sandell R; Carhart-Harris R; Gosseries O. (2025)

Current Evidence for the Role of Rapid-Acting Antidepressants in Bipolar Depression: A Perspective and Plan for Action. - Repple J; Bayas M; Möser C; Kobayashi NF; Reif A. (2025)

Exploring Public Sentiments of Psychedelics Versus Other Substances: A Reddit-Based Natural Language Processing Study - Biba B; O'Shea B. (PsyArXiv, 2025)

Extraction Yields of Psilocybin and Psilocin: A Short Review of Current Methods and Their Implications. - Galdino TP; Oliveira LC; Luz MA; Jesus RA; Lima EPN; Torres MCM; Sivieri K; Afonso VI; Delgado JMPQ; Lima AGB; Silva SML; Fook MVL. (2025)

Psychedelics and Eating Disorders: Exploring the Therapeutic Potential for Anorexia Nervosa and Beyond. - Hu S; Lin C; Wang H; Wang X. (2025)

Exploring Public Sentiments of Psychedelics Versus Other Substances: A Reddit-Based Natural Language Processing Study (PsyArXiv, 2025)

Side effects of microdosing lysergic acid diethylamide and psilocybin: A systematic review of potential physiological and psychiatric outcomes. - Modzelewski S; Stankiewicz A; Waszkiewicz N; Łukasiewicz K. (2025)